12-week Trial of IMO-2125 plus Ribavirin in Patients Infected with Hepatitis C Virus who have never before received any treatment for this infection

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-000091-33

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the safety and tolerability of different dosages of a 12-week course of IMO-2125 plus ribavirin compared to peg-rIFN plus ribavirin administered to treatment-naïve patients with chronic HCV infection


Critère d'inclusion

  • Treatment-Naive Patients Infected with Hepatitis C Virus Genotype 1

Liens